Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,666 total articles

Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026

Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026

Senseonics Holdings announced plans for an analyst event and an oral presentation at the upcoming ADA 2026 Scientific Sessions to showcase recent commercial milestones and new real-world evidence for their implantable Eversense 365 Continuous Glucose Monitoring system. These events will focus on the system's performance, integration with insulin pu…

OpenPayd Targets Nasdaq Listing at Unicorn Valuation

OpenPayd Targets Nasdaq Listing at Unicorn Valuation

OpenPayd has announced a definitive business combination with Titan Acquisition Corp. to become a publicly traded company on Nasdaq under the ticker OP. Valued at $1.145 billion on a pro-forma basis, OpenPayd operates a global financial infrastructure platform bridging traditional finance with digital assets, including stablecoins, via a single API…

NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

NextCure presented promising Phase 1 dose escalation data for SIM0505, a novel anti-CDH6 antibody-drug conjugate targeting platinum-resistant ovarian cancer (PROC) and uterine serous carcinoma (USC). The study reported a 55% overall response rate in gynecologic cancers, with favorable safety and tolerability profiles. These results support ongoing …

Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease

Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease

Voyager Therapeutics announced FDA clearance of its Investigational New Drug (IND) application for VY1706, the company's gene therapy targeting tau protein to treat Alzheimer's disease (AD). This first-of-its-kind therapy uses an intravenous brain-targeted capsid to reduce tau production, with clinical dosing expected in the second half of 2026. Pr…

Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology

Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology

Elicio Therapeutics announced the publication of a peer-reviewed study in Science Advances detailing the potent immune responses generated by their novel AMP-DNA adjuvant platform. The preclinical research highlights superior efficacy, durable T cell activation, and a distinct lymph node-targeted mechanism, reinforcing the versatility and potential…

Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma

Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma

Aura Biosciences announced the completion of enrollment for 108 patients in its pivotal Phase 3 CoMpass trial testing belzupacap sarotalocan (bel-sar) as a frontline, vision-preserving treatment for early choroidal melanoma. Topline data from the 15-month primary endpoint are anticipated in the second half of 2027, marking a key milestone toward po…

Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026

Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026

Enlivex Ltd. announced that its Phase IIa clinical trial data for Allocetra, an immunotherapy targeting moderate-to-severe knee osteoarthritis, will be presented at the EULAR 2026 congress. The data show durable and statistically significant improvements in pain reduction and function over 6 months versus placebo. These findings support the ongoing…

House of Doge and Paxos Partner to Expand Global Access to Dogecoin

House of Doge and Paxos Partner to Expand Global Access to Dogecoin

House of Doge, the corporate arm of the Dogecoin Foundation and merger partner with Brag House Holdings (NASDAQ:TBH), announced a strategic partnership with Paxos to integrate Dogecoin (DOGE) into Paxos' regulated crypto brokerage and custody platform. This integration will make Dogecoin accessible to hundreds of millions of users via Paxos' enterp…

Caring Brands Inc. and SanPellegrino Cosmetics Private Limited Announce Expanded Multi-Territory Licensing Agreement for Photocil and Hair Enzyme Booster

Caring Brands Inc. and SanPellegrino Cosmetics Private Limited Announce Expanded Multi-Territory Licensing Agreement for Photocil and Hair Enzyme Booster

Caring Brands Inc. and SanPellegrino Cosmetics Private Limited have expanded their multi-territory licensing agreement for Photocil and Hair Enzyme Booster. The revised five-year agreement broadens the commercial reach to include India, LATAM, Russia, Australia, and New Zealand. Both products have demonstrated strong clinical acceptance and commerc…

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

GT Biopharma announced successful integration of AI-based tools in their drug discovery process, enhancing the identification and engineering of tumor-targeting engagers and multi-domain proteins. This technological advancement is expected to shorten development timelines, reduce costs, and increase the likelihood of clinical success. The company a…

Melbourne Capital Group Announces Strategic Advisory Relationship with Silicon Valley Acquisition Corp.

Melbourne Capital Group Announces Strategic Advisory Relationship with Silicon Valley Acquisition Corp.

Silicon Valley Acquisition Corp., a Nasdaq-listed SPAC focusing on high-growth sectors, has appointed Melbourne Capital Group as its strategic advisor. This partnership aims to enhance Silicon Valley's access to high-quality opportunities in Asia-Pacific markets. The collaboration leverages Melbourne Capital's strong regional presence and Silicon V…

PMGC Holdings Signs Non-Binding Letter of Intent to Acquire Majority Stake in U.S.-Based Precision Machining Manufacturing Company Serving Aerospace, Space, Defense, and Semiconductor Markets

PMGC Holdings Signs Non-Binding Letter of Intent to Acquire Majority Stake in U.S.-Based Precision Machining Manufacturing Company Serving Aerospace, Space, Defense, and Semiconductor Markets

PMGC Holdings Inc. has signed a non-binding Letter of Intent to acquire a 76% controlling stake in a U.S.-based precision machining company specializing in high-tolerance CNC machining for aerospace, space, defense, semiconductor, and other industrial sectors. The target company is certified and compliant with industry standards, has recurring reve…

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Immuneering Corporation announced updated data from its Phase 2a trial showing a median overall survival of 17.3 months in first-line metastatic pancreatic cancer patients treated with atebimetinib plus modified gemcitabine/nab-paclitaxel chemotherapy, nearly double the survival seen in historical controls. The treatment demonstrated a favorable sa…